Vor says drug licensed from RemeGen succeeded in Sjögren’s study
While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune condition.
Previous Post
PSMA PET/CT Facilitates Better Long-Term Survival Rates After Salvage Radiotherapy for Recurrent PCa
Next Post
GP premises owners to merge after shareholders accept £1.8bn offer
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago